Jagsonpal Pharmaceuticals Valuation
Is JAGSNPHARM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JAGSNPHARM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: JAGSNPHARM (₹637.7) is trading above our estimate of fair value (₹480.15)
Significantly Below Fair Value: JAGSNPHARM is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JAGSNPHARM?
Key metric: As JAGSNPHARM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is JAGSNPHARM's PE Ratio? | |
|---|---|
| PE Ratio | 69.6x |
| Earnings | ₹243.00m |
| Market Cap | ₹16.91b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.2x |
| Enterprise Value/EBITDA | 51.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does JAGSNPHARM's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 35x | ||
524164 IOL Chemicals and Pharmaceuticals | 20.5x | 29.2% | ₹20.4b |
590006 Amrutanjan Health Care | 42.5x | n/a | ₹20.2b |
506197 Bliss GVS Pharma | 21.8x | n/a | ₹13.8b |
524470 Syncom Formulations (India) | 55.3x | n/a | ₹18.3b |
JAGSNPHARM Jagsonpal Pharmaceuticals | 69.6x | n/a | ₹16.9b |
Price-To-Earnings vs Peers: JAGSNPHARM is expensive based on its Price-To-Earnings Ratio (69.6x) compared to the peer average (35x).
Price to Earnings Ratio vs Industry
How does JAGSNPHARM's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 1.6x | n/a | US$70.43m |
524652 Ind-Swift | 2x | n/a | US$13.12m |
| 2 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: JAGSNPHARM is expensive based on its Price-To-Earnings Ratio (69.6x) compared to the Indian Pharmaceuticals industry average (31.7x).
Price to Earnings Ratio vs Fair Ratio
What is JAGSNPHARM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 69.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate JAGSNPHARM's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Mercury Laboratories
₹1.1b
Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.
538964
₹928.00
7D
-1.7%
1Y
15.6%
Vivimed Labs
₹410.4m
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.
VIVIMEDLAB
₹4.95
7D
0%
1Y
-45.9%
Colinz Laboratories
₹138.6m
Manufactures, markets, and trades in pharmaceutical formulations in India.
531210
₹55.02
7D
-8.8%
1Y
33.1%